Mingjun Tan Selected Research

Obesity

1/2020

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mingjun Tan Research Topics

Disease

2	Inflammation (Inflammations) 01/2020 - 01/2018
1	Fatty Liver 01/2020
1	Glucose Intolerance 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020
1	Obesity 01/2020
1	Hyperglycemia 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Wounds and Injuries (Trauma) 01/2018
1	Carcinogenesis 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018
1	Neoplasms (Cancer) 01/2018
1	Papilloma (Papillomatosis) 01/2018

Drug/Important Bio-Agent (IBA)

2	citrate-binding transport proteinIBA 01/2020 - 01/2018
1	LipidsIBA 01/2020
1	Tetradecanoylphorbol AcetateIBA 01/2018
1	Green Fluorescent ProteinsIBA 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	anthraceneIBA 01/2018
1	matrigelIBA 01/2018
1	CarcinogensIBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Cisplatin (Platino)FDA LinkGeneric 01/2018
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2018

Therapy/Procedure

1	Transplantation 01/2020
1	Therapeutics 01/2018